

Systematic review and meta-analysis of the sedative effects and safety of dexmedetomidine in patients after cardiac surgery

Junna Wu, Guofang Li, Hongyang Zhang, Hong Li

Department of Anesthesiology, the Fourth Hospital of Shijiazhuang, The Obstetrics and Gynecology Hospital of Hebei Medical University, Shijiazhuang, China

Contributions: (I) Conception and design: J Wu, H Li; (II) Administrative support: G Li; (III) Provision of study materials or patients: J Wu, G Li, H Zhang; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: J Wu, H Zhang, H Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Hong Li. No. 16, Tang Gu Bei Street, Chang'an District, Shijiazhuang, China. Email: lihong1219@163.com.

Background: In order to increase the sample size and improve the test efficiency from a statistical perspective, we conducted a combined analysis of multiple results from similar studies. In this study, we conducted a meta-analysis to investigate the sedative effect of dexmedetomidine on patients after cardiac surgery, so as to provide theoretical basis and help for clinical treatment of cardiac diseases.

Methods: The Boolean logic search method was employed to search online databases for publications, with "dexmedetomidine", "cardiac surgery", "competitive antagonist", and "analgesic sedation" used as keywords. In addition, the literature was screened for comparative studies on the use of midazolam and propofol as controls. The Newcastle-Ottawa Scale (NOS) of Cochrane Collaborative Network was used to evaluate the pathological control studies in Meta-analysis, and the star rating system (out of 9 stars) was used to measure the results from the subjects, cases and groups. Finally, a meta-analysis was performed with Review Manager software (Cochrane).

Results: Thirteen references containing mostly low-risk biases (medium-high quality) were included in this study. The meta-analysis showed no statistically obvious heterogeneity in the mechanical ventilation time (MVT) between patients in the control group (group A) or patients in the experimental group (group B) ($\text{Chi}^2=74.71$; $\text{I}^2=92\%$; P<0.00001), showing no statistical significance (Z=1.57; P=0.12). Heterogeneity was found as a complication in both groups ($\text{Chi}^2=14.82$; $\text{I}^2=60\%$; P=0.02), but fewer complications were observed in group B (Z=2.06, P=0.04). The sedative effect displayed by patients from the 2 groups during the induction of anesthesia was statistically heterogeneous ($\text{Chi}^2=6.45$; $\text{I}^2=38\%$; P=0.17), but the sedative effect in group B was shown to be greater (Z=3.31, P=0.0009).

Conclusions: Dexmedetomidine can significantly reduce the mechanical ventilation time and the incidence of complications in patients after cardiac surgery, and has a high safety and good sedative effect on patients.

Keywords: Dexmedetomidine; mechanical ventilation; anesthesia induction; midazolam

Submitted Jun 09, 2021. Accepted for publication Aug 05, 2021. doi: 10.21037/apm-21-1850 View this article at: https://dx.doi.org/10.21037/apm-21-1850

Introduction

Sedation and analgesia both play important roles in the treatment of critically ill patients. Moderate sedation in patients receiving mechanical ventilation can effectively alleviate discomfort, eliminate anxiety, reduce the stress response, increase tolerance to endotracheal tubes and mechanical ventilation, aid and improve sleep, and induce amnesic effects. Furthermore, pain during treatment reduces a patient's metabolic rate and oxygen consumption (1,2), and improper sedation may put a critically ill patient at risk. For example, undersedation can cause restlessness, increased oxygen demand, reduced human-machine coordination, and accidental extubation, while oversedation can cause disordered circulatory and respiratory functions, delayed weaning, a prolonged intensive care unit (ICU) stay, and an increased incidence of ventilator associated pneumonia (VAP) (3,4).

Dexmedetomidine is a highly selective alpha-2 (α_2) adrenergic receptor agonist, which produces corresponding pharmacological effects by acting on α_2 receptors in both the central and peripheral nervous systems (5,6). Dexmedetomidine produces sedative and hypnotic effects by acting on locus coeruleus α_2 receptors and activating endogenous sleep-promoting pathways, which allows patients to maintain non-rapid eve movement stage 3 sleep. The main characteristic of this sedative-hypnotic state is that a patient can be awakened by stimulation or language, and there is also no accompanying respiratory depression (7,8). Dexmedetomidine has the benefits of decreasing anxiety, reducing the stress response, stabilizing hemodynamics, inducing analgesia, inhibiting salivary gland secretion, combating rigors, and managing diuresis (9,10). In addition, dexmedetomidine has useful sedative effects when combined with other sedative and analgesic drugs, which can greatly reduce the need for other medications (11,12).

Dexmedetomidine can be administered by intravenous pump, intramuscular injection, intranasal drip, or buccal, mucosal, or oral administration. It has a liver first-pass elimination effect, with an oral bioavailability of 16% (13), and the plasma clearance rate of dexmedetomidine decreases as the severity of liver damage increases. The dose of dexmedetomidine can be reduced as appropriate for patients with liver damage, and patients with renal dysfunction generally do not require an adjusted dose (14). The clinical selection of analgesic and sedative drugs needs to meet the following characteristics: small effect on circulation and respiration, rapid onset and significant effect, rapid drug metabolism and small effect on liver and kidney function. At present, the commonly used drugs include benzodiazepines, propofol, $\alpha 2$ receptor agonist (dexmedetomidine), and studies have found that dexmedetomidine has a positive effect in reducing sympathetic tension, lowering blood pressure and slowing heart rate, Meta. Therefore, metaanalysis was used in this study to study the sedative effects and safety of dexmedetomidine on patients after cardiac surgery. We present the following article in accordance with

the PRISMA reporting checklist (available at https://dx.doi. org/10.21037/apm-21-1850).

Methods

Literature retrieval

Relevant documents were selected using the Boolean search method, with "dexmedetomidine", "cardiac surgery", "competitive antagonist", and "analgesic sedation", used as keywords during searches of PubMed, Medline, Embase, China Biomedical Literature Database, HowNet, Wanfang Database, Weipu Database, and Google Scholar. All literature was examined to find articles yet to be indexed by the database literature. The retrieval time is from the establishment of the database to May 30, 2021. According to RevMan 5.2 software provided by Cochrane system, the literature quality was evaluated. All kinds of search words are freely combined, and after searching for certain documents for many times, the search engine is used to trace the certain documents. And get the latest research progress after contacting experts and researchers in the field.

Inclusion and exclusion criteria

The included literatures should meet all the following criteria: (I) the subjects are patients undergoing severe cardiac surgery; (II) intervention measures for patients: Dexmedetomidine was used as sedative in the experimental group. (III) Midazolam/propofol was used as sedative in the control group. (IV) The evaluation indexes were sedation before and after operation, postoperative nausea and vomiting, recovery time, etc.

The literatures that meet any of the following criteria are excluded: (I) the included subjects have hemodynamic instability, cardiac dysfunction and central nervous system dysfunction; (II) the research types are retrospective studies, cohort studies, case reports and other non-RCT studies; (III) the included research objects are accompanied by mental diseases or infectious diseases; (IV) no valid data is provided or literature is missing; (V) the research objects or data overlap with each other. Two senior experts were required to independently screen the title, abstract, and full text of each study, and 3 preliminary experiments were completed before screening commenced. Any inconsistencies were solved by discussion between the 2 experts or arbitration by a third expert.

Quality evaluation

In this study, Cochrane Handbook5.0.2 is used to evaluate the bias risk of 12 papers included in this study, and the evaluation results are input into Review Manager5.3 software to generate the bias risk map. A star rating system (out of 9 stars) was used to measure the results from subjects, case comparison and comparison between groups. The selected literature with 7 stars or above can be considered as high quality, that is, low risk bias; References in 1 star or no star can be considered as low quality, that is, (high risk bias); References in 2–6 stars can be considered as medium quality, that is, (medium risk bias). Two experts were required for quality assessment of the literature, and three experiments had to be conducted before screening. When two experts disagree, a discussion is needed to solve the problem.

Data extraction

The data were independently extracted using an Excel spreadsheet (Microsoft Corporation), and 3 experiments had to be performed before the extraction could commence. If there was any inconsistency, it was solved by discussion between the 2 experts or by arbitration. The data included the following: the study's first listed author and its year of publication; the number of patients in the study; the grouping of the patients and the postoperative sedation methods used for group A and group B; and parameters and indicators on the level of sedation after cardiac surgery, such as mechanical ventilation time (MVT), length of stay, complications, hemodynamic indicators, and sedative effect during induction of anesthesia.

Statistical methods

The meta-analysis was conducted using Review Manager 5.3 software (Cochrane). The included studies were tested for heterogeneity, and mean differences (MD) or standardized MD (SMD) and the 95% confidence interval (CI) were used to test the efficacy of the statistical analysis. The bias risk assessment chart from the Review Manager software was applied to assess the risk bias, so when P>0.1 and I^2 <50% or P<0.1 and I^2 >50%, a fixed effects model (FEM) or a random effects model (REM) was employed.

Results

Literature collection and NOS scale rating

As shown in Figure 1, there were 250 articles searched, with 140 articles being removed after the reading of abstracts and titles and 97 being removed after a reading of the full texts. In total, 13 articles were obtained for use in our study. The excluded literature included 48 articles whose patients had not undergone cardiac surgery or had other types of system diseases, 19 articles whose research involved animal experimentation, 39 articles with repeated research participants, 63 articles with unsuccessful data extraction, 51 articles taking nonhemodynamic parameters as research indicators, and 17 articles lacking original data for the research results. The basic information from the chosen literature is shown in Table 1, including the publication date of each article (between 2003 and 2013). Figure 2 shows the results of the NOS scale rating, revealing 4 selected articles with \geq 7 stars, 9 articles with 2–6 stars, and 0 articles with <2 stars. Therefore, the articles included in our study were judged to be of medium and high quality.

Risk bias of articles

Figures 3 and *4* show the multiple risk bias evaluations, including random sequence generation, allocation hiding, blinding of result evaluation, and incomplete result data. All selected articles had a low bias level, and the blinding of the participants and researchers and other biases were about 50%. All articles except for those by Kevin *et al.* [2010] and Ghali *et al.* [2011] had a low-risk bias.

Comparison of MVT

The MVT from the patients in group A and group B were compared, as shown in *Figure 5*, with the patients described by Stephanie *et al.* [2005] accounting for the largest percentage (16.7%), followed by the patients of Akin *et al.* [2012] (15.4%) and Nihan *et al.* [2011] (14.8%). The horizontal line (HL) of the 95% CI in most studies is on the left side of the invalid vertical line (IVL), with a small number of studies seen on the right side. Group A included 347 patients, while group B and 355 patients in, with no statistical heterogeneity in MVT between the groups being found (Chi²=74.71; I²=92%; P<0.00001). The combined

Annals of Palliative Medicine, Vol 10, No 8 August 2021



Figure 1 Flowchart of the literature screening process.

effect size (CES; represented by diamond blocks in *Figure 5*) crossed the IVL, producing an odds ratio (OR) value of -2.28 and a 95% CI of -5.13 to 0.57. The random model analysis indicated an observable difference between the MVT of the 2 patients' groups (Z=1.57; P=0.12).

Figure 6 presents a funnel chart comparing the MVT of patients from the 2 groups. The concentration of circles in the top area indicates the high accuracy of the included studies. Although the chart's circles are seen on both sides of the midline, their asymmetry is indicative of the publication bias of an included study.

Comparison of patient length of stay

As illustrated in *Figure* 7, comparison and analysis of the 2 groups was carried out on the patients' length of stay after cardiac surgery, with Stephanie's *et al.* [2005] study accounting for the highest percentage of included patients (49.4%), followed by that of Shehabi *et al.* [2009] (42.6%). The HL of the 95% CI in most studies falls on the left side of the IVL, with the line falling on the right side in a small number of studies. Among the included studies, group A comprised 299 patients and group B 303 patients, with statistical heterogeneity visible in the patient length of stay (Chi²=14.62; I²=73%; P=0.006). The CES is seen to

the left of the IVL, with an OR value of -1.24 and a 95% CI of -4.35 to 1.87). The random model analysis shows no evidence of any remarkable differences in patient length of stay between the groups (Z=0.78; P=0.43).

Figure 8 is a funnel chart comparing the length of stay between the 2 groups of patients after cardiac surgery. The circles are distributed on both sides but are not symmetrical, indicating the existence of publication bias.

Comparison of incidence of complications

Comparison results of postoperative complications are illustrated in *Figure 9*. The most common complications were bradycardia, ventricular tachycardia, restlessness, nausea and vomiting, postoperative hyperglycemia, heart failure, myocardial infarction, and acute exhaustion. Research results from Shehabi *et al.* [2009] accounted for the highest percentage (24.4%), followed by the results from Akin *et al.* [2012] (15.7%) and Jose *et al.* [2009] (15.6%). The HL of the 95% CI in most studies falls to the left of the IVL, the HL of the research crosses the IVL, and a small number of studies have the HL of the 95% CI to the right of the IVL. In the 13 included studies, group A included 510 patients, group B included 526 patients, and any complications found within the 2 groups were

8956

Wu et al. Meta-analysis on patients after cardiac surgery

Author	Year of publication	Number of patients	Age	Group A	Group B	Parameters	Efficacy evaluation
Stephanie	2005	89	-	Dexmedetomidine	Propofol	MVT, length of stay, complications	Effectiveness, safety
Noorizan	2011	28	-	Dexmedetomidine	Midazolam	MVT, complications, application of vasoactive drugs	Effectiveness, safety
Daniel	2003	295	-	Dexmedetomidine	Propofol	Application of vasoactive drugs, hemodynamic indicators	Effectiveness, safety
Shehabi	2009	299	-	Dexmedetomidine	Midazolam	MVT, length of stay, hemodynamic indicators	Effectiveness, safety
Hu	2011	200	-	Dexmedetomidine	Midazolam	Complications, hemodynamic indicators	Effectiveness, safety
Jose	2009	80	-	Dexmedetomidine	Midazolam, propofol	MVT, length of stay	Effectiveness, safety
Kevin	2010	56	-	Dexmedetomidine	Propofol	MVT, length of stay, application of vasoactive drugs, hemodynamic indicators	Effectiveness, safety
Nihan	2011	72	-	Dexmedetomidine	Midazolam	MVT, hemodynamic indicators	Effectiveness, safety
Ghali	2011	120	4–12	Dexmedetomidine (nasal inhalation)	Midazolam (oral administration)	Complications, hemodynamic indicators, sedative effect	Effectiveness, safety
Akin	2012	90	2–9	Dexmedetomidine (nasal inhalation)	Midazolam (nasal inhalation)	Complications, sedative effect	Effectiveness, safety
Mostafa	2013	64	2–8	Dexmedetomidine (nasal inhalation)	Midazolam (nasal inhalation)	Complications, sedative effect	Effectiveness, safety
Koruk	2010	46	2–15	Dexmedetomidine (oral administration)	Midazolam (oral administration)	Complications, hemodynamic indicators, sedative effect	Effectiveness, safety
Mountain	2010	41	2–6	Dexmedetomidine (oral administration)	Midazolam (oral administration)	Complications, sedative effect	Effectiveness, safety

Table 1 Basic information of literatures

MVT, mechanical ventilation time.

statistically heterogeneous (Chi²=14.82; I²=60%; P=0.02). In *Figure 9*, the CES is on the left side of the IVL, with an OR value of 0.46 and a 95% CI of 0.22–0.96. The REM analysis shows lower rates of complication for patients in group B than for patients in group A (Z=2.06; P=0.04).

Figure 10 shows a funnel chart which compares the complications of the patients in groups A and B. The circles concentrated in the top area suggest the accuracy of the included studies was high. The asymmetrical distribution

on both sides of the IVL is reflective of publication bias.

Comparison of bemodynamic indicators

The hemodynamic indices of patients after cardiac surgery compared in *Figure 11* are average pulse pressure (APP), average heart rate (AHR), and blood oxygen saturation (BOS). The Mostafa *et al.* [2013] study accounted for the highest percentage of included patients (18.1%), followed by the studies of Stephanie *et al.* [2005] (17.1%) and Noorizan *et al.* [2011] (16.8%). The HL of the 95% CI in most studies is seen to fall to the left of the IVL. There is no crossover between the HL or IVL included in the research, and the HL of the 95% CI is on the right of the IVL in a small number of studies. Among the 13 included studies, there were 300 patients in group A and 317 patients in group B, reflecting statistical heterogeneity in hemodynamic indicators (Chi²=59.50; I²=92%; P<0.00001). The CES is on the left side of the IVL, while the OR value and the 95% CI are -6.10, and -10.32 to -1.88, respectively. REM analysis suggests that the hemodynamic indices of patients in group B were superior to those of group A (Z=2.83; P=0.005).

Figure 12 shows a funnel chart of the hemodynamic indices. The concentration of circles in the top area



Figure 2 The results of the NOS scale rating. NOS, Newcastle-Ottawa Scale.

indicates that the accuracy of the included studies was high. The circles are found on both sides of the midline, but they are generally asymmetrical, which is indicative of publication bias.

Comparison of anesthesia-induced sedative effects

Figure 13 shows the comparison of sedation levels for patients in group A and group B during the induction of anesthesia. Research from Akin *et al.* [2012] accounted for the highest percentage of included patients (39.5%), followed by patients in the Ghali *et al.* [2011] (19.3%) and Koruk *et al.* [2010] studies (17.4%). Most studies show the 95% CI to the right of the IVL and crossing over the HL, with the HL of the 95% CI of a small number of studies falling to the left of the IVL. There were 200 patients in each group. The sedation of patients during induction of anesthesia was statistically heterogeneous (Chi²=6.45; I²=38%; P=0.17) with the CES seen on the right side of the IVL, and an OR value and 95% CI of 2.12 and 1.36–3.31, respectively. The FEM analysis shows greater sedative effects for patients in group B (Z=3.31; P=0.0009).

Figure 14 shows a funnel chart comparing the sedative effect on patients in the 2 groups during induction of anesthesia. The circles are distributed on both sides and they are roughly symmetrical, showing no publication bias.

Discussion

Research from Ghali et al. [2011] (15) found that midazolam



Figure 3 The results of risk bias evaluations.



has many limitations and defects as a preoperative drug, potentially causing postoperative restlessness, behavioral changes, cognitive dysfunction, and respiratory depression. At present, there are many sedative drugs available for cardiac surgery patients, with dexmedetomidine, midazolam, and propofol being the more commonly used medications (16). As a highly selective α_2 receptor agonist, dexmedetomidine has good sedative and antisympathetic effects. Good sedative treatment can effectively alleviate patient discomfort and reduce the impact of external stimuli (17), and dexmedetomidine is gradually gaining attention, as it has been shown to both maintain hemodynamic stability and has an inability to induce respiratory depression (18).

Of the 13 articles in this study, 12 adopted a randomized controlled grouping method and only 1 adopted a retrospective analysis method, which might have introduced bias to our study. However, the effect on the results was minimal, as using a meta-analysis to synthesize the literature



Figure 6 A funnel chart to compare the MVT for the 2 groups of patients. SE, standard error; MD, effect size; MVT, mechanical ventilation time.



Figure 5 Comparison of the MVT for the 2 groups of patients. MVT, mechanical ventilation time.

Blinding of participants and personnel (performance bias)

?

• ? ? ? ?

? ? ?

ŧ

ŧ

• • • •

÷

• ?

? . +

? 💽 💽

Ŧ

Random sequence generation (selection bias)

•

+

•

? | ? | ? | 🕢 | 🕢 |

🕢 | 🕢 | 🕢 | 🕢 | ?) | ?)

+

(+)

+

?

Figure 4 The results of multiple risk bias evaluations.

Akin 2012

Daniel 2003

Ghali 2011

Hu 2011

Jose 2009

Kevin 2010

Koruk 2010

Mostafa 2013

Mountain 2010

Noorizan 2011

Shehabi 2009

Stephanie 2005

Nihan 2011

Allocation concealment (selection bias)

Ŧ

Blinding of outcome assessment (detection bias)

?

ncomplete outcome data (attrition bias)

?

+

? ?

(+

+

?

Selective reporting (reporting bias)

+

(()

Other bias

?

?

Ŧ

Ŧ

Annals of Palliative Medicine, Vol 10, No 8 August 2021

	Experimental		Control		Mean Difference		Mean Difference						
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Rand	om, 95% Cl		
Akin 2012	45.6	21.6	40	72	48	38	3.3%	-26.40 [-43.06, -9.74]					
Jose 2009	45.6	21.6	40	72	72	40	1.7%	-26.40 [-49.70, -3.10]					
Kevin 2010	61	33.1	28	58.67	32.61	28	3.1%	2.33 [-14.88, 19.54]			<u>†</u>		
Shehabi 2009	45	7.83	152	45	8.5	147	42.6%	0.00 [-1.85, 1.85]		3	#		
Stephanie 2005	23	1.32	43	23	1.32	46	49.4%	0.00 [-0.55, 0.55]		1	P		
Total (95% CI)			303			299	100.0%	-1.24 [-4.35, 1.87]					
Heterogeneity: Tau ² = 5.02; Chi ² = 14.62, df = 4 (P = 0.006); l ² = 73%										25	0	25	50
Test for overall effect: Z = 0.78 (P = 0.43)										experimental]	Favours [control]	

Figure 7 Comparison on the length of stay for the 2 groups of patients after cardiac surgery.



Figure 8 A funnel chart describing the stay of length for the 2 groups of patients after cardiac surgery. SE, standard error; MD, effect size.



Figure 10 A funnel chart comparing the complications for the 2 groups of patients. SE, standard error; MD, effect size.

	Experimental		erimental Control Odds Ratio		Odds Ratio	Odds Ratio			
Study or Subgroup	Events	Total	Events	ts Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl		
Akin 2012	4	40	17	40	15.7%	0.15 [0.04, 0.50]			
Daniel 2003	5	148	2	147	11.5%	2.53 [0.48, 13.28]			
Hu 2011	1	104	5	96	8.2%	0.18 [0.02, 1.54]			
Jose 2009	4	40	16	38	15.6%	0.15 [0.05, 0.52]			
Kevin 2010	5	28	4	28	13.4%	1.30 [0.31, 5.47]			
Noorizan 2011	9	14	11	14	11.3%	0.49 [0.09, 2.64]			
Shehabi 2009	56	152	70	147	24.4%	0.64 [0.40, 1.02]			
Total (95% CI)		526		510	100.0%	0.46 [0.22, 0.96]	•		
Total events	84		125						
Heterogeneity: Tau ² =	0.53; Chi ²	= 14.82	2, df = 6 (F	^o = 0.03	2); l² = 60'	%			
Test for overall effect:	Z = 2.06 (F	P = 0.04)				Eavours [experimental] Eavours [control]		



neutralizes the differences among the studies sampled from different populations. A meta-analysis can assign different weights to results, which increases a sample size and improves the credibility of conclusions (19). The number of articles included in this study was limited due to the objective influence of the literature, so sample sizes should be increased for any future investigations.

The Boolean logic search method was applied to conduct a meta-analysis on the 13 articles that described using midazolam and propofol as controls to explore the sedative

	Experimental		Control			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Ghali 2011	97.5	1.8	104	102	18	96	16.4%	-4.50 [-8.12, -0.88]	
Hu 2011	98.2	12.2	104	105.8	18.4	96	15.5%	-7.60 [-11.96, -3.24]	
Mostafa 2013	86	2.7	14	92	1.5	14	18.1%	-6.00 [-7.62, -4.38]	
Nihan 2011	77.714	9.419	38	95.333	7.071	34	16.1%	-17.62 [-21.44, -13.80]	
Noorizan 2011	76.826	4.8	14	76.33	3.7	14	16.8%	0.50 [-2.68, 3.67]	+
Stephanie 2005	55.6	7.06	43	57.6	6.81	46	17.1%	-2.00 [-4.89, 0.89]	
Total (95% CI)			317			300	100.0%	-6.10 [-10.32, -1.88]	•
Heterogeneity: Tau ² =	24.93; C	hi² = 59.							
Test for overall effect: $Z = 2.83$ (P = 0.005)									Favours [experimental] Favours [control]

Figure 11 Comparison of hemodynamic indicators for the 2 groups of patients after cardiac surgery.



Figure 12 A funnel chart showing the comparison of hemodynamic indices for the 2 groups of patients. SE, standard error; MD, effect size.



Figure 14 A funnel chart comparing the sedative effect for the 2 groups of patients during induction of anesthesia. SE, standard error; MD, effect size.

	Experimental		Experimental Control			Odds Ratio	Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl			
Akin 2012	34	50	33	50	39.5%	1.09 [0.48, 2.52]				
Ghali 2011	7	50	6	50	19.3%	1.19 [0.37, 3.84]				
Koruk 2010	24	36	14	36	17.4%	3.14 [1.20, 8.24]				
Mostafa 2013	13	32	6	32	13.3%	2.96 [0.95, 9.21]				
Mountain 2010	17	32	6	32	10.5%	4.91 [1.59, 15.16]				
Total (95% CI)		200		200	100.0%	2.12 [1.36, 3.31]	◆			
Total events	95		65							
Heterogeneity: Chi ² =	6.45, df =	4 (P = 0	17); 17 = 3							
Test for overall effect:	Z = 3.31 (^o = 0.00	09)		Favours [experimental] Favours [control]					

Figure 13 The sedative effects for the 2 groups of patients during induction of anesthesia.

effect of dexmedetomidine on patients undergoing cardiac surgery. As a result of this meta-analysis, the complications of group A and group B were statistically heterogeneous (Chi²=14.82; I²=60%; P=0.02). Patients in group B showed markedly lower complication rates (Z=2.06; P=0.04), which indicates that dexmedetomidine used for postoperative sedation effectively reduces the incidence of postoperative complications in patients. Heterogeneity of the sedative effects during anesthesia induction for patients in the 2 groups was statistically significant (Chi²=6.45; I²=38%; P=0.17), with the sedative effect of group B observed to be greater than that in group A (Z=3.31; P=0.0009). These results are consistent with the findings of Zhang *et al.* [2020] (20), which showed that dexmedetomidine has

a better sedative effect on patients and that it could also be used to largely reduce both the incidence of MVT and complications in patients after cardiac surgery.

Conclusions

The Boolean logic search method was applied to conduct a meta-analysis on the 13 articles which described using midazolam and propofol as controls, with the chosen articles being used to examine the sedative effect of dexmedetomidine on patients undergoing cardiac surgery. The results revealed that dexmedetomidine can significantly reduce the mechanical ventilation time and the incidence of complications in patients after cardiac surgery, and has a high safety and good sedative effect on patients. However, the meta-analysis was limited, as every article selected included a case-control study, so there was inherent survival bias. Furthermore, patients with varying types of heart disease and predisposing factors were included, which contributed to a reduced CES. Follow-up analysis of prospective cardiac surgery patients should consider the increased sedative effect of dexmedetomidine on patients to improve the analysis. Overall, our findings may provide a theoretical basis and data support for the future clinical treatment of heart disease.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the PRISMA reporting checklist. Available at https://dx.doi.org/10.21037/apm-21-1850

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi. org/10.21037/apm-21-1850). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons

Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- Djaiani G, Silverton N, Fedorko L, et al. Dexmedetomidine versus Propofol Sedation Reduces Delirium after Cardiac Surgery: A Randomized Controlled Trial. Anesthesiology 2016;124:362-8.
- Liu X, Xie G, Zhang K, et al. Dexmedetomidine vs propofol sedation reduces delirium in patients after cardiac surgery: A meta-analysis with trial sequential analysis of randomized controlled trials. J Crit Care 2017;38:190-6.
- Nguyen J, Nacpil N. Effectiveness of dexmedetomidine versus propofol on extubation times, length of stay and mortality rates in adult cardiac surgery patients: a systematic review and meta-analysis. JBI Database System Rev Implement Rep 2018;16:1220-39.
- Elgebaly AS, Sabry M. Sedation effects by dexmedetomidine versus propofol in decreasing duration of mechanical ventilation after open heart surgery. Ann Card Anaesth 2018;21:235-42.
- Zhu Z, Zhou H, Ni Y, et al. Can dexmedetomidine reduce atrial fibrillation after cardiac surgery? A systematic review and meta-analysis. Drug Des Devel Ther 2018;12:521-31.
- Brock L. Dexmedetomidine in Adult Patients in Cardiac Surgery Critical Care: An Evidence-Based Review. AACN Adv Crit Care 2019;30:259-68.
- Shehabi Y, Ruettimann U, Adamson H, et al. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med 2004;30:2188-96.
- Corbett SM, Rebuck JA, Greene CM, et al. Dexmedetomidine does not improve patient satisfaction when compared with propofol during mechanical ventilation. Crit Care Med 2005;33:940-5.
- Herr DL, Sum-Ping ST, England M. ICU sedation after coronary artery bypass graft surgery: dexmedetomidinebased versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth 2003;17:576-84.
- 10. Shehabi Y, Grant P, Wolfenden H, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized

Wu et al. Meta-analysis on patients after cardiac surgery

controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM Study). Anesthesiology 2009;111:1075-84.

- Hu X, Jia M, Zhao Y, et al. Sedative effect of dexmedetomidine and midazolam after cardiac surgery. Ningxia Journal of Medicine 2011;33:967-9.
- Maldonado JR, Wysong A, van der Starre PJ, et al. Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery. Psychosomatics 2009;50:206-17.
- Anger KE, Szumita PM, Baroletti SA, et al. Evaluation of dexmedetomidine versus propofol-based sedation therapy in mechanically ventilated cardiac surgery patients at a tertiary academic medical center. Crit Pathw Cardiol 2010;9:221-6.
- Abd Aziz N, Chue MC, Yong CY, et al. Efficacy and safety of dexmedetomidine versus morphine in post-operative cardiac surgery patients. Int J Clin Pharm 2011;33:150-4.
- Ghali AM, Mahfouz AK, Al-Bahrani M. Preanesthetic medication in children: A comparison of intranasal dexmedetomidine versus oral midazolam. Saudi J Anaesth 2011;5:387-91.

Cite this article as: Wu J, Li G, Zhang H, Li H. Systematic review and meta-analysis of the sedative effects and safety of dexmedetomidine in patients after cardiac surgery. Ann Palliat Med 2021;10(8):8952-8962. doi: 10.21037/apm-21-1850

- Akin A, Bayram A, Esmaoglu A, et al. Dexmedetomidine vs midazolam for premedication of pediatric patients undergoing anesthesia. Paediatr Anaesth 2012;22:871-6.
- Mostafa MG, Morsy KM. Premedication with intranasal dexmedetomidine midazolam and ketamine for children undergoing bone marrow biopsy and aspirate. Egyptian J Anaesth 2013;29:131-5.
- Koruk S, Mizrak A, Gul R, et al. Dexmedetomidineketamine and midazolam-ketamine combinations for sedation in pediatric patients undergoing extracorporeal shock wave lithotripsy: a randomized prospective study. J Anesth 2010;24:858-63.
- Mountain BW, Smithson L, Cramolini M, et al. Dexmedetomidine as a pediatric anesthetic premedication to reduce anxiety and to deter emergence delirium. AANA J 2011;79:219-24.
- 20. Zhang J, Yu Q, Liu Y, et al. Comparison of ED50 of intranasal dexmedetomidine sedation in children with acyanotic congenital heart disease before and after cardiac surgery. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:864-8.

(English Language Editors: J. Collie and J. Gray)

8962